Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$59.70 USD
+0.64 (1.08%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $59.70 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth C Momentum B VGM
Exact Sciences (EXAS) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$80.05 | $100.00 | $61.00 | 35.54% |
Price Target
Based on short-term price targets offered by 19 analysts, the average price target for Exact Sciences comes to $80.05. The forecasts range from a low of $61.00 to a high of $100.00. The average price target represents an increase of 35.54% from the last closing price of $59.06.
Analyst Price Targets (19)
Broker Rating
Exact Sciences currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 21 brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on 21 recommendations.
Of the 21 recommendations deriving the current ABR, 18 are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 18 | 18 | 17 | 16 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.30 | 1.32 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/2/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Hold | Hold |
8/1/2024 | UBS | Dan Leonard | Hold | Hold |
8/1/2024 | Craig-Hallum | William B Bonello | Not Available | Strong Buy |
8/1/2024 | The Benchmark Company | Bruce D Jackson | Hold | Hold |
7/31/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
7/19/2024 | Piper Sandler | David M Westenberg | Strong Buy | Strong Buy |
7/17/2024 | Goldman Sachs | Matthew Sykes | Strong Buy | Strong Buy |
7/8/2024 | William Blair | Andrew F Brackmann | Strong Buy | Strong Buy |
7/2/2024 | Evercore Partners | Vijay Kumar | Not Available | Strong Buy |
6/27/2024 | Scotiabank | Sung-Ji Nam | Not Available | Strong Buy |
6/26/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
6/3/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
5/9/2024 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Daniel Brennan | Strong Buy | Strong Buy |
1/29/2024 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
12/13/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 21 |
Average Target Price | $79.63 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.20 |